EP3615025A4 - Nrf and hif activators/hdac inhibitors and therapeutic methods using the same - Google Patents
Nrf and hif activators/hdac inhibitors and therapeutic methods using the same Download PDFInfo
- Publication number
- EP3615025A4 EP3615025A4 EP18790569.0A EP18790569A EP3615025A4 EP 3615025 A4 EP3615025 A4 EP 3615025A4 EP 18790569 A EP18790569 A EP 18790569A EP 3615025 A4 EP3615025 A4 EP 3615025A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- nrf
- same
- therapeutic methods
- hdac inhibitors
- hif activators
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762490101P | 2017-04-26 | 2017-04-26 | |
PCT/US2018/029258 WO2018200608A1 (en) | 2017-04-26 | 2018-04-25 | Nrf and hif activators/hdac inhibitors and therapeutic methods using the same |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3615025A1 EP3615025A1 (en) | 2020-03-04 |
EP3615025A4 true EP3615025A4 (en) | 2020-11-25 |
Family
ID=63918693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18790569.0A Pending EP3615025A4 (en) | 2017-04-26 | 2018-04-25 | Nrf and hif activators/hdac inhibitors and therapeutic methods using the same |
Country Status (9)
Country | Link |
---|---|
US (1) | US10934255B2 (en) |
EP (1) | EP3615025A4 (en) |
JP (1) | JP7396646B2 (en) |
CN (1) | CN110730660A (en) |
AU (1) | AU2018258338B2 (en) |
CA (1) | CA3056448A1 (en) |
IL (1) | IL269124B2 (en) |
MX (1) | MX2019012674A (en) |
WO (1) | WO2018200608A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102236356B1 (en) | 2017-11-24 | 2021-04-05 | 주식회사 종근당 | Compositions for Preventing or Treating Lupus |
CN109574936B (en) * | 2018-11-23 | 2022-02-22 | 沈阳药科大学 | Hydroxamic acid compound with HDAC6 inhibitory activity and application thereof |
US20220008414A1 (en) * | 2018-11-23 | 2022-01-13 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical composition comprising histone deacetylase 6 inhibitors |
WO2020167969A1 (en) * | 2019-02-15 | 2020-08-20 | Triterpenoid Therapeutics, Inc. | Methods and compositions for inhibiting the nlrp3 inflammasome and/or lon protease |
MX2022004809A (en) * | 2019-10-23 | 2022-05-16 | Chong Kun Dang Pharmaceutical Corp | Compositions for preventing or treating chronic obstructive pulmonary diseases (copd). |
CN113527206B (en) | 2020-04-17 | 2022-12-30 | 上海中泽医药科技有限公司 | Benzoazaheterocycle compound, preparation method and application thereof |
WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
CN112843038B (en) * | 2021-03-30 | 2022-05-20 | 徐州医科大学 | Application of medicine in preparation of medicine for treating diffuse large B cell lymphoma |
WO2023192424A1 (en) * | 2022-03-30 | 2023-10-05 | The Regents Of The University Of California | Volatile hd ac inhibitors for therapeutic and plant applications cross-reference to related application |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007028638A1 (en) * | 2005-09-09 | 2007-03-15 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
WO2011011186A2 (en) * | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
WO2013062344A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
WO2014181137A1 (en) * | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7528165B2 (en) * | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
US7408079B2 (en) | 2002-01-10 | 2008-08-05 | The Johns Hopkins University | Imaging agents and methods of imaging NAALADase or PSMA |
US20060183902A1 (en) | 2005-02-15 | 2006-08-17 | Baxter Ellen W | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
UA95788C2 (en) | 2005-12-15 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Fused pyrrole derivatives |
JP2009525955A (en) * | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | Histone deacetylase inhibitor |
AU2007282080B2 (en) | 2006-08-03 | 2013-06-27 | Georgetown University | Isoform-selective HDAC inhibitors |
SI2343286T1 (en) | 2006-10-28 | 2015-05-29 | Methylgene Inc. | Dibenzo(b,f)(1,4)oxazepine derivatives as inhibitors of histone deacetylase |
AU2013230881A1 (en) * | 2012-03-07 | 2014-10-30 | Board Of Trustees Of The University Of Illinois | Selective histone deactylase 6 inhibitors |
JP6726658B2 (en) * | 2014-04-11 | 2020-07-22 | イェン、ユンYEN,Yun | Histone deacetylase inhibitor |
WO2017053360A1 (en) | 2015-09-22 | 2017-03-30 | The Board Of Trustees Of The University Of Illinois | Bicyclic and tricyclic cap bearing mercaptoacetamide derivatives as histone deacetylase inhibitors |
-
2018
- 2018-04-25 MX MX2019012674A patent/MX2019012674A/en unknown
- 2018-04-25 JP JP2019557841A patent/JP7396646B2/en active Active
- 2018-04-25 AU AU2018258338A patent/AU2018258338B2/en active Active
- 2018-04-25 EP EP18790569.0A patent/EP3615025A4/en active Pending
- 2018-04-25 CA CA3056448A patent/CA3056448A1/en active Pending
- 2018-04-25 US US16/603,266 patent/US10934255B2/en active Active
- 2018-04-25 WO PCT/US2018/029258 patent/WO2018200608A1/en unknown
- 2018-04-25 CN CN201880027703.XA patent/CN110730660A/en active Pending
-
2019
- 2019-09-04 IL IL269124A patent/IL269124B2/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007028638A1 (en) * | 2005-09-09 | 2007-03-15 | Euro-Celtique S.A. | Fused and spirocycle compounds and the use thereof |
WO2011011186A2 (en) * | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
WO2013062344A1 (en) * | 2011-10-28 | 2013-05-02 | Chong Kun Dang Pharmaceutical Corp. | Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof |
WO2014181137A1 (en) * | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Novel histone deacetylase inhibitors |
Non-Patent Citations (2)
Title |
---|
See also references of WO2018200608A1 * |
TRAN-THI-LAN HUONG ET AL: "Novel N -hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity", BIOORGANIC CHEMISTRY., vol. 71, 1 April 2017 (2017-04-01), US, pages 160 - 169, XP055416602, ISSN: 0045-2068, DOI: 10.1016/j.bioorg.2017.02.002 * |
Also Published As
Publication number | Publication date |
---|---|
JP2020517688A (en) | 2020-06-18 |
AU2018258338B2 (en) | 2022-07-14 |
EP3615025A1 (en) | 2020-03-04 |
IL269124A (en) | 2019-11-28 |
CA3056448A1 (en) | 2018-11-01 |
IL269124B1 (en) | 2023-01-01 |
US20200039933A1 (en) | 2020-02-06 |
MX2019012674A (en) | 2020-02-05 |
CN110730660A (en) | 2020-01-24 |
IL269124B2 (en) | 2023-05-01 |
US10934255B2 (en) | 2021-03-02 |
WO2018200608A1 (en) | 2018-11-01 |
AU2018258338A1 (en) | 2019-11-14 |
JP7396646B2 (en) | 2023-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3615025A4 (en) | Nrf and hif activators/hdac inhibitors and therapeutic methods using the same | |
EP3634430A4 (en) | Multibiotic agents and methods of using the same | |
EP3684821A4 (en) | Anti-hla-a2 antibodies and methods of using the same | |
EP3670513A4 (en) | Fgfr inhibitor and medical application thereof | |
EP3689876A4 (en) | Pde9 inhibitor and use thereof | |
EP3633034A4 (en) | MODIFIED Cas9 PROTEIN AND USE THEREOF | |
EP3836971A4 (en) | Conjugates and methods of using the same | |
EP3585212A4 (en) | Head support and method of using the same | |
ZA201905934B (en) | Dual magl and faah inhibitors | |
EP3848377A4 (en) | Fgfr4 inhibitor and use thereof | |
EP3784650A4 (en) | Novel mct4 inhibitors and uses thereof | |
EP3659644A4 (en) | Removable apparatus and multi-dosing apparatus | |
EP3702362A4 (en) | Polypeptide having analgesic activity and use thereof | |
IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
EP3334730A4 (en) | Pyrrolomycins and methods of using the same | |
EP3697763A4 (en) | D-amino acid oxidase inhibitors and therapeutic uses thereof | |
EP3677682A4 (en) | Modified lipase and use thereof | |
EP3615502A4 (en) | Therapeutic compounds and methods | |
EP3524254A4 (en) | Lin28a ACTIVATOR AND USE THEREFOR | |
EP3568018A4 (en) | Compounds and methods use | |
EP3843742A4 (en) | Cd73 inhibitors and therapeutic uses thereof | |
EP3356418A4 (en) | Anti-podocalyxin antibodies and methods of using the same | |
EP3341739A4 (en) | Mutant peptides and methods of treating subjects using the same | |
EP3787639A4 (en) | Therapeutic uses and methods | |
EP3536782A4 (en) | Modified enzyme and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191121 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/404 20060101AFI20200720BHEP Ipc: C07D 209/04 20060101ALI20200720BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201028 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/404 20060101AFI20201022BHEP Ipc: C07D 209/04 20060101ALI20201022BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20221205 |